Therefore, along with direct mutation and promoter methylation of NRF2, mutations in Keap1 and p62, which can increase stabilization of NRF2, are crucial regulatory factors for PCa progression and therapy resistance. This evidence concerns the gene NFE2L2 and posterior cortical atrophy.